A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.

Chad J SwansonYong ZhangShobha DhaddaJinping WangJune KaplowRobert Y K LaiLars LannfeltHeather BradleyMartin RabeAkihiko KoyamaLarisa ReydermanDonald A BerryScott BerryRobert GordonLynn D KramerJeffrey L Cummings

Published in: Alzheimer's research & therapy (2021)

Clinical Trials.gov NCT01767311 .

Keyphrases

clinical trial
double blind
phase ii
placebo controlled
phase iii
open label
study protocol
cognitive decline
randomized controlled trial
mild cognitive impairment